hPD-1/hPD-L1/HLA-A2.1/B2M
Nomenclature
C57BL/6JSmo-Pdcd1tm1(hPDCD1)Cd274tm1(hPD-L1)B2mtm1(hB2M-linker-HLA-A*0201/H2-D1)Smoc
Cat. NO.
NM-XA-252092
Strain State
Repository Live
Model Description
Validation Data
Tabel 1. Body weight and organs weight of male WT C57BL/6 mice and homozygous hPD-1/hPD-L1/HLA-A2.1/B2M mice. Values are shown as Mean±SME.
Abbr. HO, homozygous; WT, wild type.
Table 2. Blood routine examination of male homozygous hPD-1/hPD-L1/HLA-A2.1/B2M mice. Values are expressed as mean±SEM.
Abbr. HO, homozygous; WT, wild type.
Table 3. Biochemical test of serum from hPD-1/hPD-L1/HLA-A2.1/B2M mice. Values are expressed as mean±SEM.
Abbr. HO, homozygous; WT, wild type.
Fig.1 Detection of (A) myeloid cell subsets and (B) lymphocyte subsets in the blood of hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by FACS. hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice showed a normal immune phenotype in blood.(n=4 in each group, 7-8 weeks old).
Abbr. WT, wild type; HO, homozygous.
Fig.2 Detection of (A) myeloid cell subsets and (B) lymphocyte subsets in the spleen of hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by FACS. hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice showed a normal immune phenotype in spleen, except for a significant decreased proportion of CD8+ T cells compared to the WT mice (n=4 in each group, 7-8 weeks old).
Abbr. WT, wild type; HO, homozygous.
Fig.3 Detection of lymphocyte subsets in lymphnodes of hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by FACS. hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice showed a normal immune phenotype in lymph nodes, except for a significant decreased proportion of CD8+ T cells compared to the WT mice (n=4 in each group, 7-8 weeks old).
Abbr. WT, wild type; HO, homozygous.
Fig.4 Pathological analysis of homozygous hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by H＆E staining. There were no obvious pathological changes in spleen, thymus, stomach, colon, brain, heart and kidney tissues in homozygous hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice (n=3, male, 7-8 weeks old, 4x magnificantion for brain and 10x magnification for other tissues).
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
